Abstract
Cancer stem cells (CSCs) are a subset of cells within tumours that have the ability to selfrenew, differentiate and resist both chemotherapy and radiotherapy. Evidence has emerged in recent years to support liver cancer stem cells (LCSCs) as the key tumour initiating cells and major drivers of tumour progression in hepatocellular carcinoma (HCC). Currently the major approaches to targeting LCSCs are ablating the expression of LCSC markers, disruption of key LCSCs signaling pathways, micro-RNA or siRNA targeting, inducing differentiation of LCSCs and the disruption of chemoresistance of LCSCs. However, complex crosstalk amongst gene regulatory pathways in LCSCs provides a major barrier in implementing these approaches in a clinical setting. Given these findings a deeper understanding of the pathways that mediate LCSC tumourigenesis is imperative for developing new therapeutic strategies for HCC and to improve clinical outcomes.
Keywords: Chemoresistance, differentiation, hepatocellular carcinoma, liver cancer stem cells, micro-RNA, self-renewal, signaling pathways.
Current Gene Therapy
Title:Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Volume: 15 Issue: 2
Author(s): Gang Zhou, George Wilson, Jacob George and Liang Qiao
Affiliation:
Keywords: Chemoresistance, differentiation, hepatocellular carcinoma, liver cancer stem cells, micro-RNA, self-renewal, signaling pathways.
Abstract: Cancer stem cells (CSCs) are a subset of cells within tumours that have the ability to selfrenew, differentiate and resist both chemotherapy and radiotherapy. Evidence has emerged in recent years to support liver cancer stem cells (LCSCs) as the key tumour initiating cells and major drivers of tumour progression in hepatocellular carcinoma (HCC). Currently the major approaches to targeting LCSCs are ablating the expression of LCSC markers, disruption of key LCSCs signaling pathways, micro-RNA or siRNA targeting, inducing differentiation of LCSCs and the disruption of chemoresistance of LCSCs. However, complex crosstalk amongst gene regulatory pathways in LCSCs provides a major barrier in implementing these approaches in a clinical setting. Given these findings a deeper understanding of the pathways that mediate LCSC tumourigenesis is imperative for developing new therapeutic strategies for HCC and to improve clinical outcomes.
Export Options
About this article
Cite this article as:
Zhou Gang, Wilson George, George Jacob and Qiao Liang, Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer, Current Gene Therapy 2015; 15 (2) . https://dx.doi.org/10.2174/1566523214666141224095938
DOI https://dx.doi.org/10.2174/1566523214666141224095938 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Current Signal Transduction Therapy Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Younger for Longer: Insulin Signalling, Immunity and Ageing
Current Aging Science Meet Our Editorial Board Member
Current Protein & Peptide Science Maximizing Baculovirus-Mediated Foreign Proteins Expression in Mammalian Cells
Current Gene Therapy Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Nutrition in Infancy
Current Pediatric Reviews A Novel Method to Synthesize 4-Aryl-1H-1,2,3-Triazoles and its Antihepatoma Activity
Anti-Cancer Agents in Medicinal Chemistry A Quantitative Proteomics Approach in the Study of MicroRNA 181a in HepG2 Cells
Current Proteomics Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry